Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IST:ONCSM's EV-to-EBITDA is ranked worse than 84.9% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.155
vs IST:ONCSM: 39.60
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's PE Ratio (TTM) for today is calculated as:
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's share price for today is ₺284.00.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺1.900.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-EBITDA Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
IST:ONCSM vs ABT, SYK, MDT: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS EV-to-EBITDA vs Medical Devices & Instruments Industry
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current Enterprise Value is ₺6,873.7 Mil.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺173.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a EV-to-EBITDA of 39.60 as of Jul. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS. This is 32% above median its historical median of 29.94. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #433 out of 510 companies in the Medical Devices & Instruments industry, placing it in the top 84.9%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EV-to-EBITDA too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-EBITDA of 39.60 is 32% above median its 10-year median of 29.94. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.16. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 39.60 is 179.8% above this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #433 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #433 out of 510 companies for EV-to-EBITDA. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the lower half of its industry. The industry median EV-to-EBITDA is 14.16. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 39.60 is 179.8% above this benchmark. While the company's 10-year median is 29.94 vs. the industry median of 14.16, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.16, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-EBITDA of 39.60 is 179.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current EV-to-EBITDA is 39.60, which is 32% above median its own 10-year median of 29.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Modestly Overvalued. The stock's GF Value™ is ₺255.12, compared to a current price of ₺284.00 — trading 11.3% above its estimated fair value. The current EV-to-EBITDA is 39.60, which is 32% above median its 10-year median of 29.94 and 179.8% above the Medical Devices & Instruments industry median of 14.16. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current EV-to-EBITDA is 39.60 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be overvalued.
The current stock price of ₺284.00 is trading 11.3% above its estimated GF Value™ of ₺255.12.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Modestly Overvalued.
Key valuation signals for IST:ONCSM:
EV-to-EBITDA: 39.60 (32% above median its 10-year median of 29.94)
GF Value™: ₺255.12 vs. price of ₺284.00 (11.3% above fair value)
Industry Position: 179.8% above the Medical Devices & Instruments median (#433 of 510)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
